The introduction of Retatrutide ZPHC, at a dosage of 120mg, is creating considerable buzz within the healthcare community. This groundbreaking dual GIP and GLP-1 receptor medication suggests to offer significant improvements in body loss compared to current therapies. Initial patient studies have demonstrated significant reductions in body mass , p